Drug intelligence / Profile preview

FM701

Development stage: Preclinical
Lead developer: AbbVie
Modality: Small Molecules

Overview

FM701 is an investigational therapeutic candidate being developed by Future Medicine Co., Ltd. for the treatment of non-small cell lung cancer (NSCLC). While specific details regarding its molecular target and modality are limited in public disclosures, it is part of Future Medicine's oncology pipeline, which focuses on developing targeted therapies for solid tumors. The drug is currently in the early stages of development, aimed at addressing the significant unmet medical need in patients with advanced or refractory NSCLC.

Targets

MDH1 (Malate dehydrogenase 1)MDH2 (Mitochondrial Malate Dehydrogenase)

Beyond the preview

Go deeper on FM701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FM701.

Explore the full profile